PTHSHealthcare · BiotechnologyThe 7 Wall Street analysts covering Pelthos Therapeutics, Inc. hold a median 12-month price target of $55 — +104.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Pelthos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (89): The shares have been drifting up relative to others.
Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Pelthos Therapeutics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on PTHS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +104.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 1 Apr 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 20 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 19 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Feb 2026 | Piper Sandler | Initiates | Overweight | — |
| 26 Feb 2026 | Roth Capital | Maintains | Buy | — |
| 26 Jan 2026 | Oppenheimer | Maintains | Outperform | — |
| 3 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 3 Dec 2025 | Lake Street | Initiates | Buy | — |
| 25 Nov 2025 | Roth Capital | Initiates | Buy | — |
| 14 Nov 2025 | Oppenheimer | Reiterates | Outperform | — |
| 2 Sept 2025 | Oppenheimer | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 35% of US stocks
Cheaper than 36% of US stocks
Cheaper than 74% of US stocks
Higher than 67% of US stocks
Higher than 65% of US stocks
Higher than 13% of US stocks
Higher than 3% of US stocks
Higher than 4% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PTHS appears on the weeks it earns a place.
Pelthos Therapeutics announced it will report its second quarter 2026 financial results on August 13, 2026. The company plans to release the results on that date.
Why it matters — The upcoming financial results will provide an update on Pelthos's recent performance and financial position.
Pelthos Therapeutics announced that its 2026 Annual Meeting of Stockholders will be held virtually on September 29, 2026. Stockholders of record as of August 4, 2026 are entitled to vote, and the proxy statement is expected to be filed in early August.
Why it matters — The announcement sets the date and voting eligibility for the annual meeting where stockholders will vote on matters such as board elections and other corporate proposals.
The 7 Wall Street analysts covering Pelthos Therapeutics, Inc. have a median 12-month price target of $55, with estimates ranging from $48 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Pelthos Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pelthos Therapeutics, Inc. 32 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Pelthos Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (89 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +104.9% from the last close, and Ticker Nerd's factor model ranks Pelthos Therapeutics, Inc. 32 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pelthos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTHS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $75 over the next 12 months.
Pelthos Therapeutics, Inc. returned +28.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for high unmet patient needs.
The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026". Pelthos Therapeutics announced it will report its second quarter 2026 financial results on August 13, 2026. The company plans to release the results on that date.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for high unmet patient needs. Its primary function is to develop and launch treatments like ZELSUVMI™, a novel therapeutic product for Molluscum contagiosum infections. Notably, Pelthos Therapeutics leverages its proprietary nitric oxide-based technology platform to address significant medical challenges. The company operates in the pharmaceutical sector, specifically targeting dermatological conditions. With a strong pipeline of potential product candidates, Pelthos aims to deliver impactful treatments to patients across various demographics. Its market significance lies in addressing unmet medical needs through pioneering therapeutic innovations.
CEO Mr. Scott M. Plesha · 92 employees · United States · https://pelthos.com